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We recently reported that a sequence variant in the cell-cycle–checkpoint kinase CHEK2 (CHEK2 1100delC) is a
low-penetrance breast cancer–susceptibility allele in noncarriers of BRCA1 or BRCA2 mutations. To investigate
whether other CHEK2 variants confer susceptibility to breast cancer, we screened the full CHEK2 coding sequence
in BRCA1/2-negative breast cancer cases from 89 pedigrees with three or more cases of breast cancer. We identified
one novel germline variant, R117G, in two separate families. To evaluate the possible association of R117G and
two germline variants reported elsewhere, R145W and I157T with breast cancer, we screened 737 BRCA1/2-
negative familial breast cancer cases from 605 families, 459 BRCA1/2-positive cases from 335 families, and 723
controls from the United Kingdom, the Netherlands, and North America. All three variants were rare in all groups,
and none occurred at significantly elevated frequency in familial breast cancer cases compared with controls. These
results indicate that 1100delC may be the only CHEK2 allele that makes an appreciable contribution to breast
cancer susceptibility.
DNA damage results in activation of cell-cycle check-
points that block proliferation and initiate DNA repair
processes. Defects of these checkpoint pathways can lead
to genomic instability and susceptibility to cancer. Cell-
cycle–checkpoint kinase 2 (CHEK2, also known as
“CHK2” [MIM 604373]), is a key mediator of cellular
responses to DNA damage (Zhou and Elledge 2000;
Bartek et al. 2001). Following double-strand DNA
breaks, CHEK2 is activated through phosphorylation by
ATM (MIM 208900) (Matsuoka et al. 1998, 2000). Ac-
tivated CHEK2 phosphorylates critical cell-cycle proteins,
including p53 (MIM 191170), Cdc25C (MIM 157680),
Cdc25A (MIM 116947), and BRCA1 (MIM 113705),
which promote cell-cycle arrest and activation of DNA
repair (Zeng et al. 1998; Chehab et al. 2000; Lee et al.
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2000; Falck et al. 2001). We recently reported that
CHEK2 1100delC, a truncating variant that abrogates
the kinase activity of the protein, is a low-penetrance
breast cancer–susceptibility allele (The CHEK2-Breast
Cancer Consortium 2002). CHEK2 1100delC was pre-
sent in 1.1% of healthy control subjects, compared with
5.1% of subjects with breast cancer from BRCA1/2-
negative families, including 13.5% of subjects from fam-
ilies with male breast cancer. We estimated that CHEK2
1100delC confers an ∼2-fold increased breast cancer risk
in women and 10-fold risk in men (The CHEK2-Breast
Cancer Consortium 2002). A study of Finnish breast
cancer cases reported a CHEK2 1100delC frequency of
1.4% in controls and 5.5% in BRCA1/2-negative fa-
milial breast cancer cases, independently supporting this
observation (Vahteristo et al. 2002).
CHEK2 1100delC was originally reported in a family
with Li-Fraumeni syndrome (LFS [MIM 151623]) that
included three cases of breast cancer (Bell et al. 1999).
Screening of cancer cases from LFS and families afflicted
with Li-Fraumeni–like syndrome (LFL) revealed two ad-
ditional CHEK2 germline sequence variants in individ-
uals with breast cancer (Bell et al. 1999; Lee et al. 2001).
R145W was initially reported in the HCT15 colorectal
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cancer cell line and, subsequently, in the germline of an
individual with sarcoma at 20 years of age, breast cancer
at 42 years of age, and a family history consistent with
LFL (Bell et al. 1999; Lee et al. 2001). The breast tumor
showed loss of the wild-type CHEK2 allele. CHEK2
R145W has been shown to be deficient in kinase activity,
binding and phosphorylation of Cdc25A, and ATM-de-
pendent phosphorylation and, thus, is plausibly asso-
ciated with the cancer susceptibility in this individual
(Wu et al. 2001; Li et al. 2002). A second reported var-
iant in CHEK2, I157T, has wild-type kinase activity but
is deficient in binding and phosphorylation of Cdc25A
and in binding to BRCA1 and p53 (Falck et al. 2001;
Wu et al. 2001; Li et al. 2002). I157T has been reported
in families with LFS, LFL, and breast cancer (Bell et al.
1999; Allinen et al. 2001; Bougeard et al. 2001; Lee et
al. 2001; Vahteristo et al. 2001; Sullivan et al. 2002).
However, I157T has also been detected in control popu-
lations at frequencies of 0%–6.5% (Bell et al. 1999; Al-
linen et al. 2001; Lee et al. 2001; Vahteristo et al. 2001).
Thus, it is unclear whether I157T is a neutral polymor-
phism or confers a small increased risk of cancer.
To identify additional CHEK2-sequence variants that
may confer susceptibility to breast cancer, we screened the
full coding sequence of CHEK2 in one case subject with
breast cancer and negative for mutations in BRCA1/2
from each of 89 families (from the United Kingdom, the
Netherlands, or North America) with at least three cases
of breast cancer. These families are referred to as the
Variant Ascertainment Set. The families with breast can-
cer were ascertained from genetics clinics, and samples
were obtained with approval of the Local Ethics Re-
search Committee/Institutional Review Board. The 76
families with breast cancer from the United Kingdom
and the United States each consisted of a minimum of
three cases of breast cancer in first- or second-degree
relatives who were diagnosed prior to age 60 years. The
13 families with breast cancer from the Netherlands con-
sisted of a minimum of three cases of breast cancer in
first- or second-degree relatives, of whom at least one
was diagnosed prior to age 60 years. Nine Dutch families
included at least three cases of breast cancer diagnosed
prior to age 60 years. At least one affected individual
from each of the 89 families was screened by Confor-
mation Sensitive Gel Electrophoresis (CSGE) (Ganguly
et al. 1993) for the full coding sequence and intron-exon
boundaries of BRCA1 and BRCA2 and was negative for
mutations. In addition, families from the Netherlands
were shown to be negative for rearrangements found
elsewhere in the Dutch population (Petrij-Bosch et al.
1997). For the CHEK2 whole gene screen, a single ge-
nomic DNA sample from each family was analyzed by
CSGE. Exons 10–14 were amplified in a long-range PCR
to avoid the partial nonprocessed genomic copies of
CHEK2 (Sodha et al. 2002). The long-range PCR was
variably successful in these analyses, but complete data
was obtained from a minimum of 76 families for each
of exons 10–13 and from 59 families for exon 14.
In total, we identified three sequence variants of
CHEK2 in the 89 cases. Five cases carried the synony-
mous A252G (E84E) variant that has been reported in
several other CHEK2 screens and is a likely neutral poly-
morphism with no elevated risk of breast cancer (Bell et
al. 1999; Hofmann et al. 2001; Ingvarsson et al. 2002;
Reddy et al. 2002; Sullivan et al. 2002). Six cases har-
bored CHEK2 1100delC and have been reported else-
where (The CHEK2-Breast Cancer Consortium 2002).
One novel variant, R117G, was detected in two separate
families, one from the United Kingdom and one from
the Netherlands (fig. 1; table 1).
To evaluate the breast cancer risk associated with
R117G and two variants, I157T and R145W, reported
elsewhere in the germline of breast cancer cases, we used
a study design similar to that employed in our previous
analysis of CHEK2 1100delC, in which the frequency
of the variant in case subjects with a family history of
the disease was compared with that in control subjects.
Although conventional association studies to detect low-
penetrance susceptibility alleles compare population-
based series of case with control subjects, use of familial
cases markedly improves the power to detect an effect.
For each variant, we screened 737 breast cancer cases
from 605 families negative for BRCA1/2 mutations, 459
cases from 335 families positive for BRCA1/2, and 723
control subjects from the United Kingdom, North Amer-
ica, and the Netherlands by means of high stringency,
allele-specific oligonucleotide (ASO) hybridization, with
sequencing of positive cases (table 1). These series are
referred to as “the Variant Evaluation Set” and did not
include any cases from the families screened in the Var-
iant Ascertainment Set. The families with breast cancer
each contained at least two individuals with breast can-
cer or one individual with breast cancer and one indi-
vidual with ovarian cancer who were first- or second-
degree relatives of one another. At least one of the
individuals with breast cancer was diagnosed before age
60 years. Families were ascertained through cancer ge-
netics clinics in the relevant countries. The United King-
dom control subjects were children from the North
Cumbria Community Genetics Project study from the
northwest of the United Kingdom (Chase et al. 1998).
The Dutch control subjects were spouses of cystic fibro-
sis heterozygotes from the southwest of the Netherlands.
The North American control subjects were neighbor-
hood control subjects from a breast cancer case-control
study in the Philadelphia area or spouses marrying-in to
families with breast cancer ascertained for linkage anal-
ysis from the same area. Each variant was detected by
PCR amplification of the relevant exon, application of
PCR products to nylon filters, and hybridization under
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Figure 1 Abridged familial pedigrees with breast cancer who were positive for CHEK2 R117G. A, Pedigrees positive for R117G, as
identified in the Variant Ascertainment Set. The index individual screened is indicated with an arrow. B, Pedigrees positive for R117G, as
identified in the Variant Evaluation Set; all three individuals were screened as part of the analyses. Filled symbols indicate individuals with
breast cancer. Hatched symbols indicate individuals with cancers other than breast cancer. bc p breast cancer; bbc p bilateral breast cancer;
crc p colorectal cancer; lu ca p lung cancer; oe ca p esophageal cancer. The age at diagnosis is indicated after the tumor type.
high stringency of 32P end-labeled oligonucleotides com-
plementary to mutant and the wild-type sequence (table
2). Every filter contained both a negative and a positive
control and was scored independently by three individ-
uals, as described elsewhere (The CHEK2-Breast Cancer
Consortium 2002).
In our analyses of the Variant Evaluation Set, we iden-
tified both R117G and I157T in 2/737BRCA1/2-negative
familial case subjects and 1/723 control subjects and
R145W in none of the case or control subjects (table 1).
Codon 117 is within the forkhead-associated (FHA)
domain of CHEK2. FHA protein motifs are phospho-
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Table 1
CHEK2 Variants in BRCA1/2-Negative Breast Cancer Cases, BRCA1/2-Positive Breast Cancer
Cases, and Controls






Families negative for BRCA1/BRCA2 in
United Kingdom 72 72 1 0 0
North America 4 4 0 0 0
Netherlands 13 13 1 0 0
Total 89 89 2 0 0
Variant Evaluation Setb:
Families negative for BRCA1/BRCA2c in
United Kingdom 241 121 2d 0 0
North America 284 272 0 0 2
Netherlands 212 212 0 0 0
Total 737 605 2 0 2
Families positive for BRCA1/BRCA2 in
United Kingdom 83 47 0 0 0
North America 235 147 0 0 0
Netherlands 141 141 0 0 0
Total 459 335 0 0 0
Control individuals in
United Kingdom 448 … 0 0 0
North America 94 … 0 0 1
Netherlands 181 … 1 0 0
Total 723 1 0 1
a Full screen of CHEK2 coding sequence.
b Allele-specific hybridization analysis of variant.
c The subjects negative for BRCA1/2 in the Variant Evaluation Set do not include any cases from
families that were screened in the Variant Ascertainment Set.
d Both individuals positive for R117G were from the same family.
peptide recognition domains (Durocher et al. 2000), and
the CHEK2 FHA domain mediates ATM-dependent
CHEK2 phosphorylation and targeting of CHEK2 to in
vivo binding partners, such as BRCA1 (Li et al. 2002).
The FHA domain is also implicated in CHEK2 oligo-
merization, which, in turn, is involved in regulation of
CHEK2 activation, signal amplification, and transduc-
tion in DNA damage checkpoint pathways (Xu et al.
2002). Arg117 is a functionally important and highly con-
served residue in the FHA domain (identical in both Sac-
charomyces cerevisiae and Schizosaccharomyces pombe).
It anchors peptides via hydrogen bonding interactions
with the phosphothreonine side chain, and disruption
by an artificially introduced Arg117rAla substitution
(R117A) severely reduces phosphopeptide binding (Li et
al. 2002). Furthermore, there is no detectable binding
of BRCA1 by R117A, in contrast to wild-type CHEK2
(Li et al. 2002). Thus, it is biologically plausible that the
R117G variant, which is likely to have similar functional
defects to R117A, confers susceptibility to breast cancer.
However, only 2/737 BRCA1/2-negative case subjects in
the Variant Evaluation Set carried R117G, and these
were from the same family. One of 723 control subjects
carried R117G (table 1). The three pedigrees afflicted
with breast cancer in either set in which R117G was
found are shown in figure 1. In one (EMC8138), all four
tested individuals affected with breast cancer carried the
variant. In the two other families (B546, B556), the var-
iant was present in only two of three tested individuals
with breast cancer. The probability that five out of the
seven secondary cases of breast cancer in these families
would carry the R117G variant, assuming that it is not
associated with an increased risk of breast cancer, is 0.13.
Codon 157 is also in the FHA domain, though remote
from the site of phosphopeptide binding (Li et al. 2002).
I157T was reported elsewhere to be present in 8.9% (7/
79) of Finnish pedigrees with hereditary breast cancer and
6.5% (13/200) of control individuals, suggesting that the
breast cancer risk, if any, is weak (Allinen et al. 2001).
Our data are consistent with this, as we identified I157T
in 2/737 BRCA1/2-negative familial cases and in 1/723
control subjects. Samples were not available to assess
segregation with the disease in either family positive for
I157T.
Although none of the three variants we identified were
associated with a statistically significantly increased risk,
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Table 2
Germline CHEK2 Variants Identified in Subjects with Breast Cancer and Probe
Sequences Used for Their Detection in ASO Analyses
Protein Change Nucleotide change Wild-Type Sequence Probe Sequence
R117G 349ArG ggtttgggagggacaaaagct ggtttgggggggacaaaagct
R145W 433CrT aaacactttcggattttcag aaacacttttggattttcag
I157T 470TrC aaaaactcttacattgcatacat aaaaactcttacactgcatacat
the CIs for the relative risk associated with these variants
are wide. For all three variants combined, the crude 95%
CIs, on the basis of the observed frequency in case and
control subjects from the Variant Evaluation Set, are
(0.21–21.3). The relative risks obtained from this data
set are an overestimate of the “true” relative risk, be-
cause the frequency of a susceptibility allele will be
higher in familial cases than unselected cases. As a com-
parison, in the analysis of CHEK2 1100delC, the esti-
mated true relative risk was approximately twofold, but
the crude relative risk on the basis of a similar series of
familial cases was approximately fivefold (5% in case
subjects vs. 1% in control subjects). Thus, the data on
the three new CHEK2 variants are consistent either with
no effect or of a relative risk comparable with that con-
ferred by CHEK2 1100delC.
Although there is considerable uncertainty about the
level of risk associated with these threeCHEK2 variants,
we can be more certain about their overall contribution
to breast cancer incidence. The upper 95% CI on the
combined frequency of these variants in breast cancer
cases with a comparable family history is 1.5% (as com-
pared with 5% for CHEK2 1100delC). We have esti-
mated elsewhere that ∼1% of breast cancer incidence
and % of the familial aggregation of the excess breast1/2
cancer risk in first-degree relatives of case subjects is li-
kelyto be due to CHEK2 1100delC. Even if the variants
evaluated in this report are associated with a risk com-
parable with CHEK2 1100delC, much !1% of the fa-
milial aggregation of breast cancer or of breast cancer
incidence overall is likely to be attributable to them.
At least two other nonsynonymous germline CHEK2
variants have been reported in breast cancer since our
analyses were performed: a R3W variant in an individual
with breast cancer and a family history of LFL (Lee et
al. 2001), and T59K, which was reported in four Ice-
landic individuals with breast cancer (Ingvarsson et al.
2002). It is possible that these or other as-yet-uniden-
tified CHEK2 variants may confer susceptibility to breast
cancer, and additional studies in other familial breast
cancer series will be of interest. However, we identified
only two individuals with variant sequences in the 89
cases that were fully screened for mutations, compared
with six occurrences of CHEK2 1100delC in the same
family set. The low frequency of CHEK2 variants other
than 1100delC in familial breast cancer cases indicates
that, even if some are associated with an increased risk,
their overall contribution to breast cancer susceptibility
is likely to be very low. The relatively high prevalence
of CHEK2 1100delC in both the British and Dutch pop-
ulations suggests that this variant is relatively old and
subject to little selective pressure. The absence of any
other protein-truncating alterations with significant fre-
quencies could simply be due to chance but might reflect
some functional constraints on the viability of individ-
uals with alternative mutations.
Since we screened familial pedigrees with breast cancer
from three specific populations, we cannot exclude the
possibility that the contribution of CHEK2 variants to
breast cancer susceptibility differs in other populations.
However, our results indicate that in North European
populations, 1100delC is responsible for almost all of
the contribution to breast cancer susceptibility made by
sequence variants of CHEK2.
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